Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

Key Points

• Renaissance Technologies increased its Taysha Gene Therapies stake by 141.5% in the first quarter, acquiring 242,103 shares for a total holding of 413,203 shares valued at approximately $1.85 million.
• Institutional investors own 77.70% of Taysha, while insider Sukumar Nagendran sold 200,000 shares for $1.25 million under a pre-arranged Rule 10b5-1 trading plan.
• Taysha shares opened at $6.68, near their 52-week high, but the company missed quarterly EPS expectations. Analysts maintain a consensus “Buy” rating with an average price target of $12.77.

Renaissance Technologies LLC raised its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 141.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 413,203 shares of the company's stock after acquiring an additional 242,103 shares during the quarter. Renaissance Technologies LLC owned approximately 0.14% of Taysha Gene Therapies worth $1,847,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in TSHA. Sei Investments Co. increased its position in shares of Taysha Gene Therapies by 7.6% in the first quarter. Sei Investments Co. now owns 51,472 shares of the company's stock valued at $230,000 after acquiring an additional 3,614 shares during the last quarter. Cetera Investment Advisers boosted its position in Taysha Gene Therapies by 34.5% during the first quarter. Cetera Investment Advisers now owns 28,450 shares of the company's stock valued at $127,000 after purchasing an additional 7,296 shares during the last quarter. Militia Capital Management LLC bought a new position in Taysha Gene Therapies in the first quarter valued at approximately $208,000. Principal Financial Group Inc. grew its stake in Taysha Gene Therapies by 26.2% in the first quarter. Principal Financial Group Inc. now owns 16,185 shares of the company's stock valued at $72,000 after purchasing an additional 3,362 shares in the last quarter. Finally, Chicago Partners Investment Group LLC increased its position in shares of Taysha Gene Therapies by 2.5% during the 1st quarter. Chicago Partners Investment Group LLC now owns 170,751 shares of the company's stock worth $763,000 after purchasing an additional 4,210 shares during the last quarter. Institutional investors own 77.70% of the company's stock.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the transaction, the insider owned 936,410 shares in the company, valued at approximately $5,843,198.40. This trade represents a 17.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company's stock.

Taysha Gene Therapies Stock Up 4.9%

Shares of TSHA opened at $6.68 on Wednesday. Taysha Gene Therapies, Inc. has a 52 week low of $2.69 and a 52 week high of $7.30. The firm has a market cap of $1.92 billion, a P/E ratio of -17.58 and a beta of 1.22. The firm's 50-day simple moving average is $6.08 and its 200 day simple moving average is $5.47. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts forecast that Taysha Gene Therapies, Inc. will post -0.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TSHA. Citigroup reiterated an "outperform" rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Wall Street Zen downgraded shares of Taysha Gene Therapies from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. BMO Capital Markets increased their price target on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the company an "outperform" rating in a research note on Tuesday, June 23rd. Finally, Bank of America lifted their price objective on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the company a "buy" rating in a research report on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $12.77.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source